SESSION 3: Inhalation Innovation:
Advanced Tools & Technologies
Thursday • November 21, 2024 • 9:30 AM–12:00 PM • Grand Ballroom
Moderator: Richard Dalby, Ph.D.
A Novel Air-Jet Dry Powder Insufflator for High Efficiency Aerosol Delivery to Small Animals
Mohammad Abdul Motalib Momin
Virginia Commonwealth University
Virginia Commonwealth University
Exploring Inhalation Powder Blend Pre-Actuation Microstructure Using X-ray Computed Tomography: Properties, Processing and Performance
Parmesh Gajjar
InformiX Pharma
InformiX Pharma
FDA Product Specific Guidances: Alternative Bioquivalence Approaches for Orally Inhaled Drug Products
Nuria Manzano
Nanopharm, an Aptar Pharma Company
Nanopharm, an Aptar Pharma Company
Leveraging Active Material Science Technologies to Mitigate Nitrosamine Risks in Pharmaceutical Products
Badre Hammond
Aptar CSP Technologies
Aptar CSP Technologies
Discover More
In-Vitro Only Bioequivalence Approach for Generic Nasal Suspensions: The Challenge & The Opportunity
Paul Martin and Ben Stafford
Intertek
Intertek
Amorphous Content in a Drug Substance: Relevance for Inhaled Products, Methods and their Validation
Mridul Majumder
M2M Pharmaceuticals
M2M Pharmaceuticals
Delivering Precision: Innovations and Best Practices in Inhaler and Nasal Spray Testing
Deborah Jones and Ben Okorodudu
Proveris Scientific Corporation
Proveris Scientific Corporation
Customized Resistance of a Capsule-Based Dry Powder Inhaler
Ameet Sule
H&T Presspart
H&T Presspart
Relvar® Ellipta Generic: Development Of Vilanterol And Fluticasone Furoate In Vitro Bioequivalent Formulations
Marco Laackmann
Harro Höfliger
Harro Höfliger
Comparison of the In-vivo Efficacy Of First and Second Generation Synthetic Lung Surfactant (SLS) Excipient Enhanced Growth (EEG) Dry Powder Formulations and Devices
Mohammad Abdul Motalib Momin
Virginia Commonwealth University
Virginia Commonwealth University
CO-ORGANIZERS
WORKSHOP PRESENTERS
EXHIBITORS
